
Elspar (asparaginasa) is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in induction of remissions of the disease in pediatric patients. Elspar is not recommended for maintenance therapy.
Elspar (asparaginasa) has to be administered to patients only in a hospital setting under the supervision of a physician who is qualified by training and experience to administer cancer chemotherapeutic agents, because of the possibility of severe reactions.
Sutent is indicated for the treatment of patients with gastrointestinal stromal tumor (GIST)